TABLE 1.

Prevalence of Resistance-associated Mutations in Pretreatment Specimens and Summary of Treatment Outcomes Among MSM with MG-NGU

		MG Cleared After:
Mutation Profile	N = 20, n (Column %)	AZM, n (Row %)	AZM + MOX, n (Row %)	AZM + MOX + DOX, n (Row %)	Unknown, n (Row %)
None	2 (10)	1 (50)	—	1 (50)	—
MRM only
A2058G	5 (25)	1 (20)	3 (60)	—	1 (20)
A2059G	5 (25)		3 (60)	1 (20)	1 (20)
MRM and nonresistance ParC mutation
A2058G and E72D	1 (5)	—	1 (100)	—	—
A2059G and P62S	2 (10)	—	2 (100)	—	—
A2059G and P62S/silent C234T	1 (5)	—	1 (100)	—	—
A2058G and S83N	1 (5)	—	1 (100)	—	—
MRM and S83I ParC mutation
A2058G and S83I	1 (5)	—	1 (100)	—	—
A2058T and S83I	1 (5)	—	1 (100)	—	—
A2059G and S83I	1 (5)	—	—	—	1 (100)

DOX, doxycycline.